ATR Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Creative Biolabs provides comprehensive support, focusing on the critical role of ATR in cancer cell survival and drug resistance. Our expertise enables the identification of optimal drug candidates, elucidation of precise mechanisms, discovery of predictive biomarkers, and strategic design of combination therapies. We deliver actionable insights and robust data packages, significantly de-risking your development journey.
Introduction of ATR Inhibitor-based DNA Damage Response-targeting Therapeutic Development Service
The DNA Damage Response (DDR) pathway is a crucial cellular network that cancer cells often exploit for survival and proliferation. Ataxia Telangiectasia and Rad3-related (ATR) kinase is a central component of this pathway, particularly in managing replication stress. Inhibiting ATR creates synthetic lethality in cancers with compromised DDR mechanisms, such as ATM or BRCA deficiencies. Preclinical data highlight ATR inhibitors' potential as monotherapies and in synergistic combinations with chemotherapy, radiotherapy, offering a promising avenue for overcoming drug resistance.
Discover how we can help - Request a consultation.
Fig.1 Replication stress induced ATR-CHK1 activation.1
What We Can Offer
Customized Service for Unique Projects
We offer highly flexible and customized service packages, adapting our expertise and cutting-edge platforms to the precise requirements of your ATR inhibitor candidate, specific cancer targets, and therapeutic objectives. This bespoke approach ensures our services are perfectly aligned to maximize your project's success.
Comprehensive Preclinical Validation
From initial target identification to robust in vivo efficacy studies, we provide end-to-end preclinical validation. This includes utilizing advanced in vitro models such as patient-derived organoids and 3D co-culture systems, alongside sophisticated in vivo models like syngeneic models for immuno-oncology combinations and patient-derived xenograft models for human relevance.
Strategic Insights for Resistance Overcoming
We provide strategic insights and actionable solutions for overcoming intrinsic and acquired drug resistance, particularly to PARP inhibitors. This includes identifying novel combination partners, optimizing dosing schedules to mitigate resistance development, and designing follow-on therapies based on identified resistance mechanisms.
Workflow of ATRi-DDR Therapeutic Development Service
Highlights
Unrivaled Expertise & Deep DDR Understanding
We possess a comprehensive understanding of all critical DDR pathways, including ATR, PARP, ATM, CHK1, and WEE1, which provides profound insights into ATR's central role in managing replication stress and exploiting synthetic lethality to target vulnerable cancer cells.
Strategic Precision & Resistance Overcoming
We strategically target cancer cells with deficiencies in DNA repair while sparing healthy cells. This precision enhances the therapeutic potential of ATR inhibitors, particularly in overcoming established drug resistance mechanisms.
Commitment to Innovation & Advanced Technologies
Our commitment to innovation is reflected in our continuous adoption of cutting-edge technologies. We leverage advanced in vitro models, such as organoids and 3D co-cultures, and sophisticated in vivo pharmacology platforms to accelerate your program.
Integrated Approach & Proven Track Record
We foster seamless collaboration across all development stages. This integrated approach, combined with our proven track record of accelerating complex drug discovery programs and contributing to the advancement of novel oncology agents.
Experience the Creative Biolabs advantage - Get a quote today.
Customer Reviews
-
Enhanced Efficacy
Using Creative Biolabs' service in our research has significantly improved our understanding of combination therapies. Their detailed preclinical data on ATR inhibitors with chemotherapy and radiotherapy provided the critical evidence needed in our research. - Jn De.
-
Overcoming Resistance
Creative Biolabs' comprehensive analysis and strategic recommendations for combining our PARP inhibitor with an ATR inhibitor provided a clear path forward, demonstrating tangible benefits in overcoming acquired resistance mechanisms. - Ay Le.
FAQs
How does Creative Biolabs' ATR inhibitor service help overcome drug resistance?
Our service targets acquired resistance, particularly to PARP inhibitors. We delve into the molecular mechanisms of resistance, such as the restoration of homologous recombination (HR) repair or the stabilization of replication forks. By precisely disrupting these compensatory pathways, our ATR inhibitor strategies can effectively re-sensitize cancer cells, enabling robust and effective combination therapies.
Can your service help with identifying biomarkers?
Yes, biomarker discovery and validation are central to our service. We employ a comprehensive suite of advanced assays, including next-generation sequencing for genomic alterations, proteomic analysis, and functional assays like DNA fiber assays to assess replication fork stability.
How does Creative Biolabs' approach to ATR inhibitor development compare to other DDR inhibitor services?
Creative Biolabs provides an integrated, end-to-end solution with over two decades of DDR biology expertise. Unlike fragmented approaches, we combine mechanistic understanding, advanced preclinical models, and robust biomarker strategies to accelerate your program, focusing on challenges like PARP inhibitor resistance and genetic vulnerabilities.
Related Services
To further support your oncology drug development efforts, Creative Biolabs offers a suite of complementary services.
PARP Inhibitor Therapeutic Development Service
This comprehensive service provides end-to-end support for the discovery, preclinical development, and strategic combination of PARP inhibitors.
Learn More →
Oncology Biomarker Discovery
We employ advanced genomic, proteomic, and functional assays to uncover biomarkers that can predict sensitivity to DDR inhibitors, including ATR inhibitors, and track their in vivo activity.
Learn More →
Custom In Vivo Oncology Models
We specialize in the development and utilization of bespoke in vivo oncology models for robust preclinical testing. This includes PDX models and syngeneic models, essential for evaluating immune-oncology combinations.
Learn More →
How to Contact Us
The promise of ATR inhibitor-based therapies in transforming cancer treatment is immense. By targeting the fundamental vulnerabilities of cancer cells, these agents represent a new frontier in precision oncology. Ready to discuss your ATR inhibitor development project? Contact us for more information and to discuss your project.
Reference
-
Mei, Lin, et al. "Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand." Journal of hematology & oncology 12.1 (2019): 43. Distributed under an Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1186/s13045-019-0733-6
For Research Use Only | Not For Clinical Use
